Evaluation of the Relevance of Comparative Genomic Hybridization in Prenatal Diagnosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04814563 |
|
Recruitment Status :
Enrolling by invitation
First Posted : March 24, 2021
Last Update Posted : April 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Pre-natal diagnosis is developing nowadays thanks to the improvement of ultrasound performances but also of genetic analysis techniques.
The karyotype was previously the reference technique for genetic analysis. The development of comparative genomic hybridization, consisting of comparative genomic hybridization on DNA sequences and allowing the diagnosis of unbalanced chromosomal rearrangements, has made it possible to increase the resolution threshold for the detection of genetic anomalies. This technique can be performed both pre and post natal. In pre-natal, the indications for this genetic study are based on ultrasound signs and are regularly updated in the international literature. Due to the complete analysis of the genome and the increase of the resolution threshold, genetic anomalies not related to the detected ultrasound pathology may be discovered and may pose ethical problems from a genetic counseling point of view.
To date, the diagnostic performance of comparative genomic hybridization as a complement to karyotype is being confirmed and needs to be clarified in order to limit the risk of incidental discovery of genetic anomalies whose significance remains unknown.
Through the study that the investigator would like to carry out, the investigator seek to evaluate the diagnostic contribution of this comparative genomic hybridization technique compared to the data provided by the karyotype according to the various ultrasound call signs on the Nancy cohort of files presented to the multidisciplinary pre-natal diagnosis committee, since the launch of the comparative genomic hybridization in Nancy in 2012 until 2018.
| Condition or disease |
|---|
| Comparative Genomic Hybridization |
| Study Type : | Observational |
| Estimated Enrollment : | 830 participants |
| Observational Model: | Cohort |
| Time Perspective: | Retrospective |
| Official Title: | Evaluation of the Contribution of Comparative Genomic Hybridization Compared to Karyotype for the Detection of Genetic Abnormalities According to Ultrasound Call Signs in Prenatal Screening: the Cohort of the Nancy Multidisciplinary Center for Prenatal Diagnosis From 2012 to 2018 |
| Actual Study Start Date : | March 30, 2021 |
| Estimated Primary Completion Date : | April 2021 |
| Estimated Study Completion Date : | April 2021 |
- CGH-array abnormality [ Time Frame: baseline ]An anomaly will be detected at CGH-array if its size is greater than or equal to 500 Kb. Size of these anomalies will be considered in a binary manner: < 10 Mb (i.e. not visible on karyotype) and ≥ 10 Mb (i.e. visible on karyotype)
- Type of ultrasound call sign [ Time Frame: baseline ]The ultrasound signs will be defined by the ultrasound technician thanks to the recommended classification
- Genotype-phenotype concordance [ Time Frame: baseline ]The genotype-phenotype concordance is defined by the cytogeneticist who delivers the results, according to the current scientific knowledge described in the literature
- Particular gravity [ Time Frame: baseline ]The particular gravity (Yes/No) of the ultrasound sign is defined after consultation between the various health professionals gathered at the multidisciplinary pre-natal diagnosis committee (gynaecologist, paediatrician, geneticist, radiologist, histopathologists, surgeons, etc.).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- CGH-array performed for ultrasound findings at the genetic laboratory of the Nancy University Hospital from 01/10/2012 to 31/12/2018
- Results of the CGH-array presented to the multidisciplinary pre-natal diagnosis committee of Nancy
Exclusion Criteria:
- patients who objected to the use of their data for research purposes when signing the informed consent form given during the genetic consultation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04814563
| France | |
| Nancy University Hospital | |
| Nancy, France, 54000 | |
| Principal Investigator: | Estelle PERDRIOLLE-GALET, Doctor | Central Hospital, Nancy, France |
| Responsible Party: | PERDRIOLLE-GALET Estelle, Doctor, Central Hospital, Nancy, France |
| ClinicalTrials.gov Identifier: | NCT04814563 |
| Other Study ID Numbers: |
2020PI288 |
| First Posted: | March 24, 2021 Key Record Dates |
| Last Update Posted: | April 6, 2021 |
| Last Verified: | April 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Prenatal diagnosis Ultrasound sign |